APO Research
Talk to an analyst

APO RESEARCH · REPORT

Durvalumab

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Durvalumab Market Analysis and Forecast 2026-2032

23 December 2025197 pages

Choose your research edition.

Industry ResearchDurvalumab Industry Research Report 2026110 pages · $2,950 USDIndustry Growth & TrendsGlobal Durvalumab Industry Growth and Trends Forecast to 203277 pages · $3,450 USDMarket StructureGlobal Durvalumab Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032172 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Durvalumab Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Durvalumab Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Durvalumab market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Durvalumab is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Durvalumab is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Durvalumab is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Durvalumab is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Durvalumab include Medimmune (AstraZeneca). etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Durvalumab, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Durvalumab, also provides the sales of main regions and countries. Of the upcoming market potential for Durvalumab, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Durvalumab sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Durvalumab market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Durvalumab sales, projected growth trends, production technology, application and end-user industry.

Durvalumab Segment by Company

Medimmune (AstraZeneca)

Durvalumab Segment by Type

2.4mL Injection

10mL Injection

Durvalumab Segment by Application

Locally Advanced Urothelial Carcinoma

Metastatic Urothelial Carcinoma

Others

Durvalumab Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Durvalumab market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Durvalumab and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Durvalumab.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Durvalumab in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Durvalumab manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Durvalumab sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Durvalumab Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. 2.4mL Injection Major Manufacturers Table 3. 10mL Injection Major Manufacturers Table 4. Global Durvalumab Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Locally Advanced Urothelial Carcinoma Major Manufacturers Table 6. Metastatic Urothelial Carcinoma Major Manufacturers Table 7. Others Major Manufacturers Table 8. Durvalumab Industry Trends Table 9. Durvalumab Industry Drivers Table 10. Durvalumab Industry Opportunities and Challenges Table 11. Durvalumab Industry Restraints Table 12. Global Durvalumab Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 13. Global Durvalumab Revenue by Region (2021-2026) & (US$ Million) Table 14. Global Durvalumab Revenue by Region (2027-2032) & (US$ Million) Table 15. Global Durvalumab Revenue Market Share by Region (2021-2026) Table 16. Global Durvalumab Revenue Market Share by Region (2027-2032) Table 17. Global Durvalumab Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (k units) Table 18. Global Durvalumab Sales by Region (2021-2026) & (k units) Table 19. Global Durvalumab Sales by Region (2027-2032) & (k units) Table 20. Global Durvalumab Sales Market Share by Region (2021-2026) Table 21. Global Durvalumab Sales Market Share by Region (2027-2032) Table 22. Global Durvalumab Revenue by Manufacturers (US$ Million) & (2021-2026) Table 23. Global Durvalumab Revenue Market Share by Manufacturers (2021-2026) Table 24. Global Durvalumab Sales by Manufacturers (US$ Million) & (2021-2026) Table 25. Global Durvalumab Sales Market Share by Manufacturers (2021-2026) Table 26. Global Durvalumab Sales Price (US$/unit) of Manufacturers (2021-2026) Table 27. Global Durvalumab Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 28. Global Durvalumab Key Manufacturers Manufacturing Sites & Headquarters Table 29. Global Durvalumab Manufacturers, Product Type & Application Table 30. Global Durvalumab Manufacturers' Establishment Date Table 31. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 32. Global Durvalumab by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 33. Global Durvalumab Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Durvalumab Revenue by Type (2021-2026) & (US$ Million) Table 35. Global Durvalumab Revenue by Type (2027-2032) & (US$ Million) Table 36. Global Durvalumab Revenue Market Share by Type (2021-2026) Table 37. Global Durvalumab Revenue Market Share by Type (2027-2032) Table 38. Global Durvalumab Sales by Type 2021 VS 2025 VS 2032 (k units) Table 39. Global Durvalumab Sales by Type (2021-2026) & (k units) Table 40. Global Durvalumab Sales by Type (2027-2032) & (k units) Table 41. Global Durvalumab Sales Market Share by Type (2021-2026) Table 42. Global Durvalumab Sales Market Share by Type (2027-2032) Table 43. Global Durvalumab Price by Type (2021-2026) & (US$/unit) Table 44. Global Durvalumab Price by Type (2027-2032) & (US$/unit) Table 45. Global Durvalumab Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 46. Global Durvalumab Revenue by Application (2021-2026) & (US$ Million) Table 47. Global Durvalumab Revenue by Application (2027-2032) & (US$ Million) Table 48. Global Durvalumab Revenue Market Share by Application (2021-2026) Table 49. Global Durvalumab Revenue Market Share by Application (2027-2032) Table 50. Global Durvalumab Sales by Application 2021 VS 2025 VS 2032 (k units) Table 51. Global Durvalumab Sales by Application (2021-2026) & (k units) Table 52. Global Durvalumab Sales by Application (2027-2032) & (k units) Table 53. Global Durvalumab Sales Market Share by Application (2021-2026) Table 54. Global Durvalumab Sales Market Share by Application (2027-2032) Table 55. Global Durvalumab Price by Application (2021-2026) & (US$/unit) Table 56. Global Durvalumab Price by Application (2027-2032) & (US$/unit) Table 57. Medimmune (AstraZeneca) Company Information Table 58. Medimmune (AstraZeneca) Business Overview Table 59. Medimmune (AstraZeneca) Durvalumab Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 60. Medimmune (AstraZeneca) Durvalumab Product Portfolio Table 61. Medimmune (AstraZeneca) Recent Development Table 62. North America Durvalumab Revenue by Type (2021-2026) & (US$ Million) Table 63. North America Durvalumab Revenue by Type (2027-2032) & (US$ Million) Table 64. North America Durvalumab Sales by Type (2021-2026) & (k units) Table 65. North America Durvalumab Sales by Type (2027-2032) & (k units) Table 66. North America Durvalumab Sales Price by Type (2021-2026) & (US$/unit) Table 67. North America Durvalumab Sales Price by Type (2027-2032) & (US$/unit) Table 68. North America Durvalumab Revenue by Application (2021-2026) & (US$ Million) Table 69. North America Durvalumab Revenue by Application (2027-2032) & (US$ Million) Table 70. North America Durvalumab Sales by Application (2021-2026) & (k units) Table 71. North America Durvalumab Sales by Application (2027-2032) & (k units) Table 72. North America Durvalumab Sales Price by Application (2021-2026) & (US$/unit) Table 73. North America Durvalumab Sales Price by Application (2027-2032) & (US$/unit) Table 74. North America Durvalumab Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 75. North America Durvalumab Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 76. North America Durvalumab Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 77. North America Durvalumab Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 78. North America Durvalumab Sales by Country (2021-2026) & (k units) Table 79. North America Durvalumab Sales by Country (2027-2032) & (k units) Table 80. North America Durvalumab Sales Price by Country (2021-2026) & (US$/unit) Table 81. North America Durvalumab Sales Price by Country (2027-2032) & (US$/unit) Table 82. United States Durvalumab Revenue (2021-2032) & (US$ Million) Table 83. Canada Durvalumab Revenue (2021-2032) & (US$ Million) Table 84. Mexico Durvalumab Revenue (2021-2032) & (US$ Million) Table 85. Europe Durvalumab Revenue by Type (2021-2026) & (US$ Million) Table 86. Europe Durvalumab Revenue by Type (2027-2032) & (US$ Million) Table 87. Europe Durvalumab Sales by Type (2021-2026) & (k units) Table 88. Europe Durvalumab Sales by Type (2027-2032) & (k units) Table 89. Europe Durvalumab Sales Price by Type (2021-2026) & (US$/unit) Table 90. Europe Durvalumab Sales Price by Type (2027-2032) & (US$/unit) Table 91. Europe Durvalumab Revenue by Application (2021-2026) & (US$ Million) Table 92. Europe Durvalumab Revenue by Application (2027-2032) & (US$ Million) Table 93. Europe Durvalumab Sales by Application (2021-2026) & (k units) Table 94. Europe Durvalumab Sales by Application (2027-2032) & (k units) Table 95. Europe Durvalumab Sales Price by Application (2021-2026) & (US$/unit) Table 96. Europe Durvalumab Sales Price by Application (2027-2032) & (US$/unit) Table 97. Europe Durvalumab Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 98. Europe Durvalumab Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 99. Europe Durvalumab Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 100. Europe Durvalumab Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 101. Europe Durvalumab Sales by Country (2021-2026) & (k units) Table 102. Europe Durvalumab Sales by Country (2027-2032) & (k units) Table 103. Europe Durvalumab Sales Price by Country (2021-2026) & (US$/unit) Table 104. Europe Durvalumab Sales Price by Country (2027-2032) & (US$/unit) Table 105. Germany Durvalumab Revenue (2021-2032) & (US$ Million) Table 106. France Durvalumab Revenue (2021-2032) & (US$ Million) Table 107. U.K. Durvalumab Revenue (2021-2032) & (US$ Million) Table 108. Italy Durvalumab Revenue (2021-2032) & (US$ Million) Table 109. Russia Durvalumab Revenue (2021-2032) & (US$ Million) Table 110. Spain Durvalumab Revenue (2021-2032) & (US$ Million) Table 111. Netherlands Durvalumab Revenue (2021-2032) & (US$ Million) Table 112. Switzerland Durvalumab Revenue (2021-2032) & (US$ Million) Table 113. Sweden Durvalumab Revenue (2021-2032) & (US$ Million) Table 114. Poland Durvalumab Revenue (2021-2032) & (US$ Million) Table 115. China Durvalumab Revenue by Type (2021-2026) & (US$ Million) Table 116. China Durvalumab Revenue by Type (2027-2032) & (US$ Million) Table 117. China Durvalumab Sales by Type (2021-2026) & (k units) Table 118. China Durvalumab Sales by Type (2027-2032) & (k units) Table 119. China Durvalumab Sales Price by Type (2021-2026) & (US$/unit) Table 120. China Durvalumab Sales Price by Type (2027-2032) & (US$/unit) Table 121. China Durvalumab Revenue by Application (2021-2026) & (US$ Million) Table 122. China Durvalumab Revenue by Application (2027-2032) & (US$ Million) Table 123. China Durvalumab Sales by Application (2021-2026) & (k units) Table 124. China Durvalumab Sales by Application (2027-2032) & (k units) Table 125. China Durvalumab Sales Price by Application (2021-2026) & (US$/unit) Table 126. China Durvalumab Sales Price by Application (2027-2032) & (US$/unit) Table 127. Asia Durvalumab Revenue by Type (2021-2026) & (US$ Million) Table 128. Asia Durvalumab Revenue by Type (2027-2032) & (US$ Million) Table 129. Asia Durvalumab Sales by Type (2021-2026) & (k units) Table 130. Asia Durvalumab Sales by Type (2027-2032) & (k units) Table 131. Asia Durvalumab Sales Price by Type (2021-2026) & (US$/unit) Table 132. Asia Durvalumab Sales Price by Type (2027-2032) & (US$/unit) Table 133. Asia Durvalumab Revenue by Application (2021-2026) & (US$ Million) Table 134. Asia Durvalumab Revenue by Application (2027-2032) & (US$ Million) Table 135. Asia Durvalumab Sales by Application (2021-2026) & (k units) Table 136. Asia Durvalumab Sales by Application (2027-2032) & (k units) Table 137. Asia Durvalumab Sales Price by Application (2021-2026) & (US$/unit) Table 138. Asia Durvalumab Sales Price by Application (2027-2032) & (US$/unit) Table 139. Asia Durvalumab Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 140. Asia Durvalumab Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 141. Asia Durvalumab Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 142. Asia Durvalumab Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 143. Asia Durvalumab Sales by Country (2021-2026) & (k units) Table 144. Asia Durvalumab Sales by Country (2027-2032) & (k units) Table 145. Asia Durvalumab Sales Price by Country (2021-2026) & (US$/unit) Table 146. Asia Durvalumab Sales Price by Country (2027-2032) & (US$/unit) Table 147. Japan Durvalumab Revenue (2021-2032) & (US$ Million) Table 148. South Korea Durvalumab Revenue (2021-2032) & (US$ Million) Table 149. India Durvalumab Revenue (2021-2032) & (US$ Million) Table 150. Australia Durvalumab Revenue (2021-2032) & (US$ Million) Table 151. Taiwan Durvalumab Revenue (2021-2032) & (US$ Million) Table 152. Southeast Asia Durvalumab Revenue (2021-2032) & (US$ Million) Table 153. SAMEA Durvalumab Revenue by Type (2021-2026) & (US$ Million) Table 154. SAMEA Durvalumab Revenue by Type (2027-2032) & (US$ Million) Table 155. SAMEA Durvalumab Sales by Type (2021-2026) & (k units) Table 156. SAMEA Durvalumab Sales by Type (2027-2032) & (k units) Table 157. SAMEA Durvalumab Sales Price by Type (2021-2026) & (US$/unit) Table 158. SAMEA Durvalumab Sales Price by Type (2027-2032) & (US$/unit) Table 159. SAMEA Durvalumab Revenue by Application (2021-2026) & (US$ Million) Table 160. SAMEA Durvalumab Revenue by Application (2027-2032) & (US$ Million) Table 161. SAMEA Durvalumab Sales by Application (2021-2026) & (k units) Table 162. SAMEA Durvalumab Sales by Application (2027-2032) & (k units) Table 163. SAMEA Durvalumab Sales Price by Application (2021-2026) & (US$/unit) Table 164. SAMEA Durvalumab Sales Price by Application (2027-2032) & (US$/unit) Table 165. SAMEA Durvalumab Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 166. SAMEA Durvalumab Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 167. SAMEA Durvalumab Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 168. SAMEA Durvalumab Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 169. SAMEA Durvalumab Sales by Country (2021-2026) & (k units) Table 170. SAMEA Durvalumab Sales by Country (2027-2032) & (k units) Table 171. SAMEA Durvalumab Sales Price by Country (2021-2026) & (US$/unit) Table 172. SAMEA Durvalumab Sales Price by Country (2027-2032) & (US$/unit) Table 173. Brazil Durvalumab Revenue (2021-2032) & (US$ Million) Table 174. Argentina Durvalumab Revenue (2021-2032) & (US$ Million) Table 175. Chile Durvalumab Revenue (2021-2032) & (US$ Million) Table 176. Colombia Durvalumab Revenue (2021-2032) & (US$ Million) Table 177. Peru Durvalumab Revenue (2021-2032) & (US$ Million) Table 178. Saudi Arabia Durvalumab Revenue (2021-2032) & (US$ Million) Table 179. Israel Durvalumab Revenue (2021-2032) & (US$ Million) Table 180. UAE Durvalumab Revenue (2021-2032) & (US$ Million) Table 181. Turkey Durvalumab Revenue (2021-2032) & (US$ Million) Table 182. Iran Durvalumab Revenue (2021-2032) & (US$ Million) Table 183. Egypt Durvalumab Revenue (2021-2032) & (US$ Million) Table 184. Key Raw Materials Table 185. Raw Materials Key Suppliers Table 186. Durvalumab Distributors List Table 187. Durvalumab Customers List Table 188. Research Programs/Design for This Report Table 189. Authors List of This Report Table 190. Secondary Sources Table 191. Primary Sources List of Figures Figure 1. Durvalumab Image Figure 2. Global Durvalumab Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Durvalumab Market Size Share 2021 VS 2025 VS 2032 Figure 4. 2.4mL Injection Image Figure 5. 10mL Injection Image Figure 6. Global Durvalumab Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Durvalumab Market Size Share 2021 VS 2025 VS 2032 Figure 8. Locally Advanced Urothelial Carcinoma Image Figure 9. Metastatic Urothelial Carcinoma Image Figure 10. Others Image Figure 11. Global Durvalumab Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Durvalumab Revenue (2021-2032) & (US$ Million) Figure 13. Global Durvalumab Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 14. Global Durvalumab Revenue Market Share by Region: 2025 Versus 2032 Figure 15. Global Durvalumab Revenue Market Share by Region (2021-2032) Figure 16. Global Durvalumab Sales (2021-2032) & (k units) Figure 17. Global Durvalumab Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 18. Global Durvalumab Sales Market Share by Region (2021-2032) Figure 19. US & Canada & Mexico Durvalumab Sales YoY (2021-2032) & (k units) Figure 20. Europe Durvalumab Sales YoY (2021-2032) & (k units) Figure 21. China Durvalumab Sales YoY (2021-2032) & (k units) Figure 22. Asia (Excluding China) Durvalumab Sales YoY (2021-2032) & (k units) Figure 23. South America, Middle East and Africa Durvalumab Sales YoY (2021-2032) & (k units) Figure 24. Global Durvalumab Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 25. Global Durvalumab Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 26. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. Global Durvalumab Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global Durvalumab Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 29. Global Durvalumab Revenue Market Share by Type (2021-2032) Figure 30. Global Durvalumab Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 31. Global Durvalumab Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 32. Global Durvalumab Sales Market Share by Type (2021-2032) Figure 33. Global Durvalumab Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 34. Global Durvalumab Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 35. Global Durvalumab Revenue Market Share by Application (2021-2032) Figure 36. Global Durvalumab Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 37. Global Durvalumab Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 38. Global Durvalumab Sales Market Share by Application (2021-2032) Figure 39. North America Durvalumab Revenue Share by Type (2021-2032) Figure 40. North America Durvalumab Sales Share by Type (2021-2032) Figure 41. North America Durvalumab Revenue Share by Application (2021-2032) Figure 42. North America Durvalumab Sales Share by Application (2021-2032) Figure 43. North America Durvalumab Revenue Share by Country (2021-2032) Figure 44. North America Durvalumab Sales Share by Country (2021-2032) Figure 45. Europe Durvalumab Revenue Share by Type (2021-2032) Figure 46. Europe Durvalumab Sales Share by Type (2021-2032) Figure 47. Europe Durvalumab Revenue Share by Application (2021-2032) Figure 48. Europe Durvalumab Sales Share by Application (2021-2032) Figure 49. Europe Durvalumab Revenue Share by Country (2021-2032) Figure 50. Europe Durvalumab Sales Share by Country (2021-2032) Figure 51. China Durvalumab Revenue Share by Type (2021-2032) Figure 52. China Durvalumab Sales Share by Type (2021-2032) Figure 53. China Durvalumab Revenue Share by Application (2021-2032) Figure 54. China Durvalumab Sales Share by Application (2021-2032) Figure 55. Asia Durvalumab Revenue Share by Type (2021-2032) Figure 56. Asia Durvalumab Sales Share by Type (2021-2032) Figure 57. Asia Durvalumab Revenue Share by Application (2021-2032) Figure 58. Asia Durvalumab Sales Share by Application (2021-2032) Figure 59. Asia Durvalumab Revenue Share by Country (2021-2032) Figure 60. Asia Durvalumab Sales Share by Country (2021-2032) Figure 61. SAMEA Durvalumab Revenue Share by Type (2021-2032) Figure 62. SAMEA Durvalumab Sales Share by Type (2021-2032) Figure 63. SAMEA Durvalumab Revenue Share by Application (2021-2032) Figure 64. SAMEA Durvalumab Sales Share by Application (2021-2032) Figure 65. SAMEA Durvalumab Revenue Share by Country (2021-2032) Figure 66. SAMEA Durvalumab Sales Share by Country (2021-2032) Figure 67. Durvalumab Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Durvalumab Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • 2.4mL Injection
  • 10mL Injection
Applications
  • Locally Advanced Urothelial Carcinoma
  • Metastatic Urothelial Carcinoma
  • Others
Companies covered
  • Medimmune (AstraZeneca)

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Durvalumab Market by Type
  3. 1.2.1 Global Durvalumab Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 2.4mL Injection
  5. 1.2.3 10mL Injection
  6. 1.3 Durvalumab Market by Application
  7. 1.3.1 Global Durvalumab Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Locally Advanced Urothelial Carcinoma
  9. 1.3.3 Metastatic Urothelial Carcinoma
  10. 1.3.4 Others
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Durvalumab Market Dynamics
  1. 2.1 Durvalumab Industry Trends
  2. 2.2 Durvalumab Industry Drivers
  3. 2.3 Durvalumab Industry Opportunities and Challenges
  4. 2.4 Durvalumab Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Durvalumab Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Durvalumab Revenue by Region
  3. 3.2.1 Global Durvalumab Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Durvalumab Revenue by Region (2021-2026)
  5. 3.2.3 Global Durvalumab Revenue by Region (2027-2032)
  6. 3.2.4 Global Durvalumab Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Durvalumab Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Durvalumab Sales by Region
  9. 3.4.1 Global Durvalumab Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Durvalumab Sales by Region (2021-2026)
  11. 3.4.3 Global Durvalumab Sales by Region (2027-2032)
  12. 3.4.4 Global Durvalumab Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Durvalumab Revenue by Manufacturers
  2. 4.1.1 Global Durvalumab Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Durvalumab Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Durvalumab Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Durvalumab Sales by Manufacturers
  6. 4.2.1 Global Durvalumab Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Durvalumab Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Durvalumab Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Durvalumab Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Durvalumab Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Durvalumab Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Durvalumab Manufacturers, Product Type & Application
  13. 4.7 Global Durvalumab Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Durvalumab Market CR5 and HHI
  16. 4.8.2 2025 Durvalumab Tier 1, Tier 2, and Tier 3
5 Durvalumab Market by Type
  1. 5.1 Global Durvalumab Revenue by Type
  2. 5.1.1 Global Durvalumab Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Durvalumab Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Durvalumab Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Durvalumab Sales by Type
  6. 5.2.1 Global Durvalumab Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Durvalumab Sales by Type (2021-2032) & (k units)
  8. 5.2.3 Global Durvalumab Sales Market Share by Type (2021-2032)
  9. 5.3 Global Durvalumab Price by Type
6 Durvalumab Market by Application
  1. 6.1 Global Durvalumab Revenue by Application
  2. 6.1.1 Global Durvalumab Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Durvalumab Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Durvalumab Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Durvalumab Sales by Application
  6. 6.2.1 Global Durvalumab Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Durvalumab Sales by Application (2021-2032) & (k units)
  8. 6.2.3 Global Durvalumab Sales Market Share by Application (2021-2032)
  9. 6.3 Global Durvalumab Price by Application
7 Company Profiles
  1. 7.1 Medimmune (AstraZeneca)
  2. 7.1.1 Medimmune (AstraZeneca) Company Information
  3. 7.1.2 Medimmune (AstraZeneca) Business Overview
  4. 7.1.3 Medimmune (AstraZeneca) Durvalumab Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Medimmune (AstraZeneca) Durvalumab Product Portfolio
  6. 7.1.5 Medimmune (AstraZeneca) Recent Developments
8 North America
  1. 8.1 North America Durvalumab Market Size by Type
  2. 8.1.1 North America Durvalumab Revenue by Type (2021-2032)
  3. 8.1.2 North America Durvalumab Sales by Type (2021-2032)
  4. 8.1.3 North America Durvalumab Price by Type (2021-2032)
  5. 8.2 North America Durvalumab Market Size by Application
  6. 8.2.1 North America Durvalumab Revenue by Application (2021-2032)
  7. 8.2.2 North America Durvalumab Sales by Application (2021-2032)
  8. 8.2.3 North America Durvalumab Price by Application (2021-2032)
  9. 8.3 North America Durvalumab Market Size by Country
  10. 8.3.1 North America Durvalumab Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Durvalumab Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Durvalumab Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Durvalumab Market Size by Type
  2. 9.1.1 Europe Durvalumab Revenue by Type (2021-2032)
  3. 9.1.2 Europe Durvalumab Sales by Type (2021-2032)
  4. 9.1.3 Europe Durvalumab Price by Type (2021-2032)
  5. 9.2 Europe Durvalumab Market Size by Application
  6. 9.2.1 Europe Durvalumab Revenue by Application (2021-2032)
  7. 9.2.2 Europe Durvalumab Sales by Application (2021-2032)
  8. 9.2.3 Europe Durvalumab Price by Application (2021-2032)
  9. 9.3 Europe Durvalumab Market Size by Country
  10. 9.3.1 Europe Durvalumab Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Durvalumab Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Durvalumab Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Durvalumab Market Size by Type
  2. 10.1.1 China Durvalumab Revenue by Type (2021-2032)
  3. 10.1.2 China Durvalumab Sales by Type (2021-2032)
  4. 10.1.3 China Durvalumab Price by Type (2021-2032)
  5. 10.2 China Durvalumab Market Size by Application
  6. 10.2.1 China Durvalumab Revenue by Application (2021-2032)
  7. 10.2.2 China Durvalumab Sales by Application (2021-2032)
  8. 10.2.3 China Durvalumab Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Durvalumab Market Size by Type
  2. 11.1.1 Asia Durvalumab Revenue by Type (2021-2032)
  3. 11.1.2 Asia Durvalumab Sales by Type (2021-2032)
  4. 11.1.3 Asia Durvalumab Price by Type (2021-2032)
  5. 11.2 Asia Durvalumab Market Size by Application
  6. 11.2.1 Asia Durvalumab Revenue by Application (2021-2032)
  7. 11.2.2 Asia Durvalumab Sales by Application (2021-2032)
  8. 11.2.3 Asia Durvalumab Price by Application (2021-2032)
  9. 11.3 Asia Durvalumab Market Size by Country
  10. 11.3.1 Asia Durvalumab Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Durvalumab Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Durvalumab Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Durvalumab Market Size by Type
  2. 12.1.1 SAMEA Durvalumab Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Durvalumab Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Durvalumab Price by Type (2021-2032)
  5. 12.2 SAMEA Durvalumab Market Size by Application
  6. 12.2.1 SAMEA Durvalumab Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Durvalumab Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Durvalumab Price by Application (2021-2032)
  9. 12.3 SAMEA Durvalumab Market Size by Country
  10. 12.3.1 SAMEA Durvalumab Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Durvalumab Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Durvalumab Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Durvalumab Value Chain Analysis
  2. 13.1.1 Durvalumab Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Durvalumab Production Mode & Process
  6. 13.2 Durvalumab Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Durvalumab Distributors
  9. 13.2.3 Durvalumab Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst